The diagnostic status of chronic kidney disease in a real-world database in Japan: CHECK-CKD
Open Access
- 27 May 2025
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 29 (9) , 1-11
Abstract
Background: The clinical practice guidelines for chronic kidney disease (CKD) in 2018 and the launch of the first therapeutic agent in 2021 are expected to have improved CKD management in Japan. However, the reality of CKD diagnosis in this environment is poorly understood. Here, we conducted a retrospective observational study. Methods: We investigated the changes in CKD diagnosis rates, the characteristics of diagnosed cases, and the prognostic impact of the timing of diagnosis by using a database of administrative claims and medical checkups from 2014 to 2023 (DeSC Healthcare Inc.™) for patients with a potential risk of CKD (eGFR 2 and/or urine protein qualitative test result of ≥1+). Results: We extracted 287,999 patients who newly met the diagnostic criteria for CKD at a medical checkup. The rate of new CKD diagnosis remained ~ 3% until 2021. Factors associated with CKD diagnosis included blood/urine tests at a medical institution (odds ratio [OR] 4.11, 95% confidence interval [CI] 3.92–4.31; OR 5.02, 95% CI 4.82–5.22) and presence of comorbidities: anemia (OR 2.30; 95% CI 2.16–2.45), heart failure (OR 1.87; 95% CI 1.76–1.98), and diabetes (OR 1.84; 95% CI 1.76–1.91). The incidence of cardiorenal-related events at 36 months after the date when patients newly met the CKD diagnostic criteria was 4.5% and 12.4% for those diagnosed at stage 3a and 3b, respectively. Conclusions: The prevalence of CKD diagnosis was low and renal function tests were infrequently performed. Periodic blood/urine tests may help clinicians to detect CKD in an early phase. Study registration: UMIN000052393Keywords
Funding Information
- Ono Pharmaceutical Co., Ltd.
This publication has 21 references indexed in Scilit:
- Nationwide questionnaire survey on the management of chronic kidney disease for general practitioners in JapanClinical and Experimental Nephrology, 2021
- The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney International, 2021
- Hyperuricemia in Kidney Disease: A Major Risk Factor for Cardiovascular Events, Vascular Calcification, and Renal DamageSeminars in Nephrology, 2020
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- New measures against chronic kidney diseases in Japan since 2018Clinical and Experimental Nephrology, 2019
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- NoticeKidney International Supplements, 2013
- Age and Association of Kidney Measures With Mortality and End-stage Renal DiseaseJAMA, 2012
- Prevalence of chronic kidney disease in the Japanese general populationClinical and Experimental Nephrology, 2009
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001